ZDoggMD on Precision Medicine: The Promise, the Hype, and What's Actually Delivering

This article discusses ideas from ZDoggMD — Dr. Zubin Damania, MD , Stanford/UCSF-trained internist, founder of the Health 3.0 movement. Full archive: zdoggmd.com | YouTube @zdoggmd

Precision medicine — using genomic, proteomic, and other biomarker data to tailor treatments to individual patients rather than to average populations — has been one of the most exciting promises in modern medicine. ZDoggMD has tracked its progress with measured enthusiasm: some genuinely transformative applications exist now, and they exist alongside substantial hype about a future that is arriving slowly.

Where Precision Medicine Is Delivering Now

Oncology is the clearest success story: HER2-targeted therapies in breast cancer, EGFR-targeted therapies in lung cancer, BRAF inhibitors in melanoma, and CAR-T cell therapies in hematologic malignancies represent genuine precision medicine advances that have meaningfully extended survival for patients with those specific molecular profiles. Pharmacogenomics — using genetic variants to predict drug metabolism and toxicity — has practical clinical applications in anticoagulation, clopidogrel prescribing, and psychiatric medication selection.

ZDoggMD's assessment: in the domains where precision medicine is working, it's genuinely working. The transformation is real. The gap is between targeted cancer therapy (where molecular target and therapeutic response are tightly linked) and the broader vision of genomic personalization of all medicine (where polygenic traits, gene-environment interactions, and biological complexity make simple genotype-to-phenotype predictions unreliable).

The Health Disparities Problem

Most genomic databases underlying precision medicine tools are predominantly derived from European-ancestry populations. This underrepresentation means precision medicine tools perform less well — sometimes significantly less well — in patients of non-European ancestry. A field built on personalization has built-in population-level bias. ZDoggMD has highlighted this as a health equity issue that precision medicine must address to fulfill its promise equitably.

Precision Documentation for Complex Oncology Visits

Precision medicine appointments are information-dense: genomic results, targeted therapy options, clinical trial eligibility, informed consent. NoPajamaTime captures it all accurately so nothing gets lost.